Evidence map›Paper›PMID 29709937›Full record

ArticleInternal medicine (Tokyo, Japan)2018

The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma.

Naoya Nagaya, Mayuko Kanayama, Masayoshi Nagata, Shigeo Horie

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Noninvasive circulating tumor cell and urine cellularTranslational cancer research · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Naoya NagayaDepartment of Urology, Juntendo University Graduate School of Medicine, Japan.
Mayuko KanayamaDepartment of Urology, Juntendo University Graduate School of Medicine, Japan.
Masayoshi NagataDepartment of Urology, Juntendo University Graduate School of Medicine, Japan.
Shigeo HorieDepartment of Urology, Juntendo University Graduate School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are a promising biomarker for several cancers. We streamlined the experimental procedure of CTC immunofluorescent staining. We encountered a 72-year-old woman with metastatic right renal cell carcinoma (RCC) (clinical stage: T4N0M1), whose CTC number rapidly increased after the administration of sunitinib and then gradually decreased. The change in the CTC number appeared to coincide with laboratory data and hypertension, suggesting that a CTC analysis may be useful for promptly monitoring the treatment response. Our data provided the first evidence of an association between the CTC numbers and the treatment response in a metastatic RCC patient.

Indexed as

AgedAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellCell CountFemaleFluorescent Antibody TechniqueHumansIndolesKidney NeoplasmsNeoplastic Cells, CirculatingPyrrolesSunitinibAntineoplastic AgentsBiomarkers, TumorIndolesPyrrolesSunitinibcirculating tumor cellsrenal cell carcinomasunitinib

Identifiers

PMID29709937
PMCPMC6191600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.